MapLight Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
MapLight Therapeutics to Participate in Upcoming Investor Conferences
Maplight Therapeutics (NASDAQ:MPLT) is now covered by analysts at
Weiss Ratings. They set a "sell (e)" rating on the stock.
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 [Yahoo! Finance]
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026